ReviewDrugs2009
Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.
Review in Drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Optimizing fluconazole dosing in acute renal failure patients undergoing continuous renal replacement therapy: A population pharmacokinetic/pharmacodynamic study.Frontiers in pharmacology · 2025Article
- Article
- Candida albicans Hyphal Morphogenesis within Macrophages Does Not Require Carbon Dioxide or pH-Sensing Pathways.Infection and immunity · 2023Article
- Evaluation of Anti-Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Early Empirical Anidulafungin Reduces the Prevalence of Invasive Candidiasis in Critically Ill Patients: A Case-control Study.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2022Article
- Disseminated Pulmonary Mycosis Caused byCase reports in pediatrics · 2022Article
- Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?Infection · 2021Review
- Article
- Observational
- The Role of IL-17 in Protection against Mucosal Candida Infections.Journal of fungi (Basel, Switzerland) · 2017Review
- A Risk Score for Fluconazole Failure among Patients with Candidemia.Antimicrobial agents and chemotherapy · 2017Article
- Intraluminal Release of an Antifungal β-Peptide Enhances the Antifungal and Anti-Biofilm Activities of Multilayer-Coated Catheters in a Rat Model of Venous Catheter Infection.ACS biomaterials science & engineering · 2016Article
- Editorial: Antifungal Drug Discovery: New Theories and New Therapies.Frontiers in microbiology · 2016Article
- Antifungal Activity of 14-Helical β-Peptides against Planktonic Cells and Biofilms of Candida Species.Pharmaceuticals (Basel, Switzerland) · 2015Article
- A real time PCR assay on blood for diagnosis of invasive candidiasis in immunocompromised patient.Current medical mycology · 2015Article
- Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Article
- Role of neutrophils in IL-17-dependent immunity to mucosal candidiasis.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Invasive fungal infections in the ICU: how to approach, how to treat.Molecules (Basel, Switzerland) · 2014Review
- Inactivation of Candida biofilms by non-thermal plasma and its enhancement for fungistatic effect of antifungal drugs.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida spp. are an increasing cause of bloodstream infections, and are associated with high morbidity and mortality in both neutropenic and non-neutropenic critically ill patients. Risk factors associated with candidaemia are diverse and include exposure to broad spectrum antimicrobial agents, mucosal colonization by Candida spp., indwelling vascular catheters, prior surgery and cancer chemotherapy. During the last 20 years, there has been an increasing incidence worldwide in invasive candidiasis, but differences in geographical epidemiology are emerging, in particular regarding a shift towards non-albicans species. This shift has been correlated with routine fluconazole prophylaxis adopted in some patients, and the intrinsic/acquired azole resistance of Candida spp., which represents a very real problem, in terms of both selecting the appropriate empirical therapeutic approach and making prophylactic choices.
Indexed as
Identifiers
19877728What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.